

Index

A

- Apolipoprotein E (APOE), 61, 315
- Abacavir, 45, 46, 47, 109, 116, 136
- Absorption, metabolism, distribution and elimination (ADME), 4, 46, 51, 56, 94
- Adverse drug reaction (ADR), 2, 4, 45, 61, 333
 - immune-mediated, 113, 115
 - nonimmune-mediated, 124, 125
- Alzheimer's disease (AD), 3, 4, 61
- Antineoplastics, 4, 276
- Asthma, 4, 31, 242, 244, 245, 247, 251, 254, 256, 258, 262, 265

B

- Biobanks, 32, 365, 366, 367, 368
- Bioinformatics, 3, 6, 33, 53, 80, 82, 83, 86, 352, 367
- Biomarker, 3, 5, 45, 46, 61, 62, 99, 104, 136, 165, 168, 262, 277, 288, 292, 295, 338, 352, 356
- Biomarker-driven prescribing, 332
- Biomarkers, 70, 75, 76, 78, 79
 - numerous, 73
 - type of, 70, 72

C

- Cancer, 4, 25, 29, 31, 93, 97, 136, 277, 286, 291, 292, 332
 - ovarian, 3, 26, 31
 - thyroid, 27
- Clinical guidelines, 104, 117, 133, 337, 358
- Clinical trials, 5, 49, 50, 60, 100, 158, 265, 290, 296, 320, 361, 363, 364, 366
- Codeine, 97, 103, 127, 129

Companion diagnostics

- adoption of, 335
- Coumarins, 308, 309, 320
- CYP2C9, 98, 100, 130, 132, 310, 314
- CYP2C19, 97, 103, 338
- CYP2D6, 94, 97, 129, 130, 132, 286, 353

D

- Data analysis, 70, 76, 80, 81, 342, 352, 367
 - methods, 76
- Data protection, 23, 364
- Drug development, 3, 4, 6, 44, 49, 51, 54, 352, 368
- Drug transporters, 4, 94, 95, 99

E

- Ethical approval, 9, 24, 138, 353, 370
- Ethnic variations, 94
- Evidence-based medicine (EBM), 30

G

- Genetic-guided therapy, 334
- Genetic test uptake, 352, 356, 357, 358
- Genomic medicine, 5, 335, 336, 344
 - in health care, 5
- Genotype-guided prescribing, 265
- Germ-line, 4, 276, 335

H

- Hydroxyurea treatment, 15
- Hypersensitivity, 46, 109, 120

I

- Individualized therapy, 285, 360
- Informed consent, 5, 14, 33, 49, 168, 353, 355, 359, 361, 362, 365, 366

M

Malignant hyperthermia (MH), 125, 126
 Modeling, 13
 Monogenic disorders, 18, 22, 30

N

Next generation sequencing (NGS), 10, 110, 137, 339, 352

P

Parkinson's disease (PD), 4
 Personalised medicine, 44
 Pharmacodynamics, 92, 122, 335
 Pharmacogenetic-guided dosing, 5, 316, 319, 320
 Pharmacogenetics (PGx), 3, 4, 45, 46, 82, 93, 113, 124, 136, 138, 243, 308, 314, 315
 application of, 86
 aspiration of, 136
 development of, 70
 implementation, 265, 282
 implementation of, 85
 translational, 116, 117
 Pharmacogenetic technologies, 3, 4, 22, 131
 Pharmacogenomics, 2, 3, 4, 5, 167, 168, 354, 357, 369
 application of, 161
 Pharmacokinetics, 3, 92, 94, 96, 98, 101, 309, 334
 Pipeline Pharmacogenetics, 45, 62
 Predictive, 2, 3, 4, 17, 25, 30, 53, 277, 356
 biomarkers, 295
 pre-therapy, 136

Predictive genetics, 2, 30, 33, 337
 Predictive genotyping, 113
 Pretreatment genotyping, 320
 Preventive genetics, 25, 32
 Project management methodology, 56
 Public health genomics, 10, 23

S

Screening programmes, 8, 9, 10, 11, 20
 Sickle cell disease (SCD), 2, 158
 Simulation, 104
 Single nucleotide polymorphisms (SNP), 95, 96, 126, 161, 166, 338, 343
 Somatic, 276, 357
 alterations, 276
 biomarkers, 287
 mutations, 4
 Statin, 20, 94, 96, 134
 therapy, 134, 135
 Statistics, 61, 79, 80, 137, 262
 clinical, 86
 population, 73
 Study design optimisation, 53, 60, 62, 334

T

Therapeutic drug monitoring, 102
 Thromboembolic events, 308, 311, 312, 317, 319, 320
 Translation, 60, 129, 136, 296, 332
 Transporters, 95, 96, 98, 99, 102, 135

W

Warfarin, 23, 45, 98, 100, 103, 130, 310, 333
 genotype-guided, 319